rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone + liposomal cytarabine + methotrexate

This is a multi-agent chemotherapy regimen composed of seven drugs: - **Rituximab** (a monoclonal antibody targeting CD20 on B cells, used for immunotherapy) - **Cyclophosphamide** (an alkylating agent that crosslinks DNA, leading to cell death) - **Doxorubicin** (an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II) - **Vincristine** (a vinca alkaloid that inhibits microtubule formation in mitosis) - **Prednisolone** (a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects) - **Liposomal cytarabine** (a liposome-formulated nucleoside analog inhibiting DNA synthesis, often used for CNS prophylaxis or treatment in hematologic malignancies) - **Methotrexate** (an antimetabolite and antifolate agent inhibiting dihydrofolate reductase) This combination is not a standard named protocol but represents an intensified regimen likely designed for aggressive lymphomas or leukemias requiring both systemic and central nervous system-directed therapy. Each component has a distinct mechanism of action targeting malignant lymphoid cells through immune-mediated destruction, inhibition of cell division, induction of apoptosis, or suppression of inflammation.